Treatment of AD with Dupilumab

Dupilumab is a monoclonal antibody that works by inhibiting the activity of interleukin-4 and interleukin-13, two cytokines that play an integral role in the T helper 2 (Th2) immune response. It is FDA approved for the treatment of atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis. For AD treatment, it is recommended for patients ≥6 months of age with moderate-to-severe disease who have not responded to conventional topical therapies. Numerous randomized controlled trials have established dupilumab as one of the most efficacious and arguably the safest systemic therapy available for the treatment of AD. The most commonly reported side effects include conjunctivitis, facial erythema, and injection site reactions. Because of its superior efficacy and side effect profile, dupilumab has in recent years become a first-line option among systemic AD treatments.